NCT03801902 2025-09-23Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 TrialNational Cancer Institute (NCI)Phase 1 Completed26 enrolled 17 charts
NCT02671435 2025-07-22A Study of Durvalumab (MEDI4736) and Monalizumab in Solid TumorsMedImmune LLCPhase 1/2 Active not recruiting383 enrolled 48 charts
NCT03794544 2022-02-24Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerMedImmune LLCPhase 2 Completed84 enrolled 17 charts
NCT02557516 2019-12-17Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLLInnate PharmaPhase 1/2 Terminated22 enrolled 16 charts